Patient survival after renal transplantation III: The effects of statins

American Journal of Kidney Diseases

Volumn 40, Issue 3, 2002, Pages 638-643

  Cosio, Fernando G ^a   Pesavento, Todd E ^a   Pelletier, Ronald P ^a   Henry, Mitchell ^a   Ferguson, Ronald M ^a   Kim, Sunny ^a   Lemeshow, Stanley ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Kidney; Lipids; Statins; Survival; Transplantation

Indexed keywords

ANTILIPEMIC AGENT; AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036723912     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.34927     Document Type: Article

References (28)

1. Clinical epidemiology of cardiovascular disease in chronic renal disease
2. Long-term survival in renal transplant recipients with graft function
3. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors
4. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant
5. Pre-emptive transplants for patients with renal failure: An argument against waiting until dialysis
6. Effect of waiting time on renal transplant outcome
7. Management of hypertension after transplantation
8. Hyperlipidemia and transplantation: Etiologic factors and therapy
9. Hyperlipidemia in solid organ transplantation
10. Explained and unexplained ischemic heart disease risk after renal transplantation
11. Risk factors for accelerated atherosclerosis in renal transplant recipients
12. Changes in risk factors and the decline in mortality from cardiovascular disease: The Framingham study
13. The Framingham study: Its 50-year legacy and future promise
14. Statins and risk of coronary heart disease
15. Systematic review on the risk and benefit of different cholesterol-lowering interventions
16. Impact of serum lipids on long-term graft and patient survival after renal transplantation
17. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data
18. Statin trials and goals of cholesterol-lowering therapy after AMI
19. Lovastatin treatment of hypercholesterolemia in renal transplant recipients
20. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine
21. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients
22. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects
23. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
24. Statins and the acute-phase response
25. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease
26. Are there potential non-lipid-lowering uses of statins?
27. Lipophilic statins induce apoptosis of human vascular smooth muscle cells